PTK2B

Across TCGA pan-cancer cohorts, PTK2B mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of PTK2B’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where PTK2B mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types PTK2B is over-expressed in tumor, although a few such as COAD and LUAD show the opposite, repressed pattern.

HNSC, COAD, and LUAD are the cancer types where PTK2B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PTK2B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	All	+0.513	<.001	12	view →
COAD	Female	III,IV	−0.250	<.001	9	view →
LUAD	Female	II,III,IV	−0.321	<.001	7	view →
PDAC	Female	All	+0.492	<.001	4	view →
LSCC	Male	II,III,IV	−0.236	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

PTK2B–HNSC

Open the HNSC breakdown →